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CC BY-NC-ND license (http://creativeAbstract Osteosarcoma is a primary bone tumor that affects children and young adults. The
estrogen metabolite 2-methoxyestradiol (2-ME) induces cell death in osteosarcoma cells. To
determine whether 2-ME actions involve the control of protein synthesis, we studied the effect
of 2-ME on eukaryotic initiation factor 4E (eIF4E) and eIF4E-binding protein 1 (4E-BP1) in MG63
osteosarcoma cells. Our results show that 2-ME treatment increases the association of eIF4E
with 4E-BP1 in osteosarcoma cells. Also, 2-ME decreases the binding of eIF4E protein to 7-
methyl-guanosine cap structure, indicating that 2-ME treatment results in the inhibition of
translational initiation. These findings are further supported by the inhibition of protein syn-
thesis in 2-ME-treated osteosarcoma cells. Taken together, our studies show that 2-ME-medi-
ated antitumor effects in osteosarcoma cells involve the regulation of protein synthesis, and
translational machinery could serve as a target in the treatment of osteosarcoma.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Osteosarcoma is a pediatric malignancy. Even though a
combination of surgery and chemotherapy has improved
the survival rate, the mortality rate remains high for this
disease. 2-Methoxyestradiol (2-ME) is a metabolite of 17b-
estradiol that exerts antitumor effects in a number of
tumor cells, including osteosarcoma.1e7 We have previouslyand hosting by Elsevier B.V. This is an open access article under the
4.0/).
154 A. Maran et al.shown that 2-ME induces apoptosis in osteosarcoma cells,
but not in normal osteoblasts.5,8
Protein synthesis regulation has been implicated in the
control of tumor cell proliferation and apoptosis. Protein
synthesis comprises three steps: initiation, elongation, and
termination. The majority of the regulation takes place at
the level of translation initiation involving eukaryotic
translation initiation factor (eIF) 4E. eIF4E is a part of a
multiprotein eIF4F complex, which consists of three pro-
teins: eIF4E, which binds the 50 cap structure of the mRNA;
eIF4A, an ATP-dependent RNA helicase that is expected to
unwind the secondary structures in mRNA; and eIF4G, a
protein that interacts with eIF4E, eIF4A, and other initia-
tion factors to form a scaffold.9e11 The eIF4E serves as a
rate-limiting factor of the eIF4F complex and is required by
almost all mRNAs to be translated into proteins. eIF4E binds
to 7-methyl guanosine triphosphate cap, which is present in
most mRNAs, and thereby brings them to ribosomes and
regulates cap-dependent protein synthesis.12 The eIF4E
activity is regulated by eIF4E-binding proteins (4E-BPs) that
function as translational inhibitors.12e15 The 4E-BP binding
to eIF4E is determined by its phosphorylation status. The
dephosphorylated 4E-BP binds to eIF4E and thereby blocks
its activity.12,13 RNA dependent protein kinase (PKR) is
another protein which has been implicated in the regula-
tion of protein synthesis and induction of apoptosis in a
variety of different tumor cells.16e18 PKR has been shown to
act through the phosphorylation of eIF-2a.8,16e18 Previous
studies demonstrate the involvement of translational con-
trol and the components of eIF4F complex in malignant
transformation and progression.12,19 The goal of this study
was to investigate the role of initiation factors eIF4E and
4E-BP1 in 2-ME-mediated actions in osteosarcoma cells.
Materials and methods
Cell culture and metabolite treatment
MG63 osteosarcoma cells and normal human osteoblast
(HOB) cells5 were maintained in Dulbecco’s modified eagles
medium (DMEM)/F12 containing 10% charcoal-stripped fetal
bovine serum and supplemented with 100 units/mL peni-
cillin and 100 mg/mL streptomycin and maintained at
37.4,20 Cells were treated with 10 mM 2-ME (Sigma Chemi-
cal Co., St. Louis, MO) or the vehicle (70% ethanol) for
indicated periods of time.
Preparation and analysis of cytoplasmic extract
Cells were harvested after vehicle and 2-ME treatment and
lysed in cell lysis buffer, as described.21,22 Following
centrifugation, the supernatant was collected, and protein
concentration was determined by as described.21 Cyto-
plasmic extracts (60 mg protein) were analyzed by Western
blot using anti-eIF4E, anti-eIF4E-BP1, antiphospho-eIF4E-
BP1 (Thr37/46), anti-nonphospho-eIF4E-BP1 (Thr46) (Cell
Signaling, Danvers, MA), and anti-actin antibodies (Sigma)
as described in our earlier reports.21,22
Immunoprecipitation analysis was carried out as
described.22 Briefly, cytoplasmic extracts containing 60 mgprotein were used for immunoprecipitation with anti-4E-
BP1 antibodies. Bound proteins were purified using pro-
tein A Sepharose and analyzed by western blot hybridiza-
tion using anti-4E antibodies. The levels of proteins on the
western blots were quantitated using densitometer and
Quantity one 4.5.2 software (BioRad, Hercules, CA).
Cap-binding assay
Cap-binding assay by m7GTP-Sepharose chromatography
was performed as described.23 About 250 mL cell lysate
(100 mg protein) was added to 20 mL of packed m7GTP-
Sepharose beads to capture eIF4E and its binding partner
proteins. Captured proteins were eluted with buffer con-
taining 50 mM Tris (pH 8.0); 150 mM NaCl; 1mM EDTA; 0.1%
IPEGAL and 0.2% gelatin and analyzed by western blot using
anti-eIF4E directly or after immunoprecipitation with anti-
eIF4E-BP1 antibodies.
Protein synthesis (3H-leucine incorporation)
The rate of protein synthesis was measured as described.15
Briefly, protein synthesis was studied following vehicle and
2-ME (10 mM) treatment and by pulse labeling of cells for 1 h
with 10 mCi/mL of 3H-labled leucine. The cells were har-
vested and washed in 5 mL of cold phosphate buffered
saline, and then the cells were lysed and precipitated with
10% trichloroacetic acid (TCA). The precipitate was filtered
and washed with 5% TCA, and the TCA-insoluble radioac-
tivity was determined by scintillation counting.
Statistical analysis
All values are expressed as means  standard error. The
data are representative of four independent experiments.
Significant differences between groups were determined by
Fisher’s protected least significant difference post hoc test
for multiple-group comparisons following detection of sig-
nificance by one-way analysis of variance.
Results and discussion
Effect of 2-ME on initiation factors eIF4E and 4E-
BP1 in osteosarcoma cells
To determine the effect of 2-ME on protein synthesis, we
have investigated whether 2-ME regulates the binding of
protein synthesis initiation factor eIF4E to its inhibitor
protein 4E-BP1. We have analyzed the cytoplasmic extracts
from vehicle and 2-ME-treated MG63 cells by co-
immunoprecipitation studies which show that 2-ME treat-
ment increased the binding of 4E-BP1 to eIF4E at 16 and
24 h (Fig. 1A). Furthermore, the cap-binding assays carried
out show that 2-ME treatment resulted in decreased binding
of eIF4E to cap structure (Fig. 1B). In eukaryotic cells, eIF4E
associates with ribosomes and facilitates cap-dependent
mRNA translation.12,14,24,25 Studies suggest that cancer
cells depend more on cap-dependent translation than
normal cells, and cap-dependent translation is essential for
Figure. 1 2-ME regulates eIF4E and 4E-BP1 functions in osteosarcoma cells. Cytoplasmic extracts were prepared from MG63
osteosarcoma cells (A, B) at 16 and 24 h and normal human osteoblast (HOB) cells (C, D) at 24 h following vehicle (Veh) and 2-ME
treatment. The extracts were subjected to immunoprecipitation (IP) with anti-4E-BP1 antibodies (A, C) or cap-binding (B, D) and
analyzed by western blot analysis using anti-eIF4E antibodies.
2-ME treatment regulates protein synthesis 155the synthesis of tumorigenic proteins.26 In addition, eIF4E is
required for the transport of specific mRNAs. The eIF4E-
mediated regulation of gene expression exhibits different
gene specificities, as some genes are being regulated at the
level of translation and others at the level of both transport
and translation.12,25,27 Deregulated transport of mRNAs of
oncogenes and growth regulatory genes appears to be the
cause for the oncogenic functions of eIF4E.12,27 Our current
results show that an increased association of eIF4E and 4E-
BP1 is accompanied by decreased binding of eIF4E to 7-
methyl guanosine cap structure in the presence of 2-ME
treatment. Furthermore, our results demonstrate that
these effects are specific to osteosarcoma cells, and 2-MEFigure. 2 Effect of 2-ME treatment on eIF4E and 4E-BP1
expression levels. Cytoplasmic extracts were prepared
following 16 and 24 h of vehicle and 2-ME treatment from MG63
cells and analyzed by western blot using anti-eIF4E, anti-4E-
BP1, antiphospho-4E-BP1 (Thr37/46), anti-nonphospho-4E-BP1
(Thr46), and anti-actin antibodies.treatment does not affect the binding of eIF4E to 4E-BP1
(Fig. 1C) and cap structure (Fig. 1D) in normal HOB cells.
The western blot analysis shows that 2-ME treatment
does not affect the levels of eIF4E and control actin, but
modulates 4E-BP1 protein levels in MG63 cells (Fig. 2). The
results show that overall band intensity ratio in vehicle andFigure. 3 2-ME treatment downregulates protein synthesis
in osteosarcoma cells. Protein synthesis was measured
following vehicle and 2-ME treatment in MG63 (A) and HOB (B)
cells at 12, 16, and 24 h through pulse labeling with 3H-leucine.
*P < 0.01 vs vehicle.
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1:20, respectively, when probed with the anti-4E-BP1,
phospho-4E-BP1, and non-phospho-4E-BP1 antibodies.
Similarly, the ratios at 24 h were 1.4:1.0; 1.0:1.6 and 1: 60
when probed with the anti-4E-BP1, phospho-4E-BP1, and
non-phospho-4E-BP1 antibodies. Thus, these results point
out that 2-ME treatment increases the non-phospho-4E-BP1
levels more compared to phospho-4E-BP1 protein levels.
Published reports indicate that eIF4E and 4E-BP1 interac-
tion is controlled by phosphorylation of the 4E-BPs.14,15
There are 3 different types of 4E-BPs, and the hypo-
phosphorylated forms of 4E-BPs interact with high affinity
to competitively inhibit the binding of eIF4G to eIF4E.28
Conversely, phosphorylation of 4E-BPs decreases the affin-
ity of the protein for eIF4E and facilitates the binding of
eIF4E to cap structure and continuous protein synthesis in
cells.14,24 Current studies show that higher levels of non-
phosphorylated or hypophosphorylated forms of 4E-BP1
are present in the presence of 2-ME treatment compared to
vehicle controls. 4E-BPs could be phosphorylated at multi-
ple sites, and hyperphosphorylation has been shown to be
required for the dissociation of eIF4E and activation of
eIF4E functions.13,23 Also, a large number of studies report
that protein kinase mTOR (mammalian target of rapamycin)
is the major protein responsible for the 4E-BP phos-
phorylation.13,25e28 While our results clearly show an in-
crease in non-phospho 4E-BP1 protein, additional
investigations are required to establish the involvement of
mTOR, and to delineate the various forms of the phos-
phorylated and non-phosphorylated forms of 4E-BP1 in 2-
ME-treated osteosarcoma cells.
Changes in the state of phosphorylation of the 4E-BP and
in the extent of its association with eIF4E could occur inFigure. 4 2-ME effect on protein synthesis is decreased in ce
expressing vector (pcDNA) and PKRmutant protein were treated wit
were subjected to cap-binding (A) or IP with anti-4E-BP1 antibod
antibodies. Protein synthesis was measured through pulse labeling
(C). *P < 0.01 vs Veh, #P < 0.01 vs pcDNA 2-ME.response to stimulation of cell death in cells. Previous re-
ports show that the growth-inhibiting apoptotic activities of
cytokines and drugs have an impact on the eIF4E/4E-BP
system. TNFa has been shown to inhibit overall translation
in breast cancer cells by mechanisms that involve
decreased phosphorylation of 4E-BP1 and increased asso-
ciation of eIF4E and 4E-BP1.29 This observation is in
agreement with the increased association of eIF4E with 4E-
BP1 and decreased binding of eIF4E to cap structure
observed in 2-ME-treated osteosarcoma cells. Hence, this
indicates that the antitumor actions of 2-ME, in part, could
be at the level of eIF4E-dependent translation initiation.
Our result is corroborated by the absence of eIF4E regula-
tion in HOB cells that are resistant to 2-ME-mediated anti-
growth effects.Effect of 2-ME on protein synthesis
To determine whether 2-ME-mediated inhibition of eIF4E
has any effect on protein synthesis, we have followed the
rate of protein synthesis. Our findings from 3H-labeling
studies show that the rate of protein synthesis is signifi-
cantly (P < 0.1) reduced in MG63 cells to 68%, 32%, and
9.8%, respectively, at 12, 16, and 24 h in the presence of 2-
ME compared to controls (Fig. 3A). However, 2-ME treat-
ment does not affect protein synthesis in HOB cells (Fig. 3B)
and it is in agreement with the absence of regulation of
eIF4E and 4E-BP1 in HOB cells. Thus, the inhibition of eIF4E
through sequestration by inhibitory protein 4E-BP1 leads to
a block in protein synthesis in the presence of 2-ME. We
have also observed that 2-ME inhibits protein synthesis in a
number of osteosarcoma cell lines (A. Maran, K. Shogren,lls expressing PKRmutant protein. MG63 osteosarcoma cells
h vehicle and 2-ME for 24 h. The cytoplasmic extracts prepared
ies (B) and analyzed by western blot analysis using anti-eIF4E
with 3H-leucine following 24 h of vehicle and 2-ME treatment
2-ME treatment regulates protein synthesis 157M.J. Yaszemski, unpublished observations). Future in-
vestigations are necessary to identify the associated
mechanism and the target mRNAs that undergo trans-
lational block in the presence of 2-ME treatment.
Effect of 2-ME on MG63 cells expressing negative
dominant mutant PKR protein
MG63 osteosarcoma cells expressing PKRmutant protein are
resistant to 2-ME-mediated antigrowth effects.4,8,20 We
have studied the effect of 2-ME on eIF4E binding to cap
structure and to the inhibitory protein 4E-BP1 in cells
expressing negative dominant mutant PKR (PKRmutant) and
the control vector (pcDNA). Our results show that 2-ME
treatment decreased the association of eIF4E with 4E-BP1
(Fig. 4A) and increased the binding of eIF4E to cap structure
in control pcDNA cells but not in PKRmutant osteosarcoma
cells (Fig. 4B). Furthermore, the studies reveal a partial
reversal in 2-ME-mediated inhibition of protein synthesis in
PKRmutant cells (Fig. 4C). Our results show that, compared
to vehicle, 2-ME treatment decreases protein synthesis to
2% and 15% in MG63 cells expressing pcDNA and PKRmutant,
respectively (Fig. 4). Our previous studies show that 2-ME
treatment regulates the initiation factor, eIF2a, and in-
duces phosphorylation of eIF2a through the activation of
PKR.8 Current studies indicate that PKR could be involved in
additional translational regulations in 2-ME-treated osteo-
sarcoma cells involving eIF4E in addition to already
demonstrated initiation factor eIF-2a-dependent
mechanisms.
Conclusion
In this report, we have shown a direct relationship between
the assembly of the cap-dependent translation initiation
apparatus and the antitumor effects of 2-ME. Our results
show that 2-ME treatment in osteosarcoma cells resulted in
a) increased association of eIF4E with eIF4E-BP1; b)
decreased binding of eIF4E to 7-methyl guanosine cap
structure; c) increased levels of hypophosphorylated 4E-
BP1 protein; and d) decreased protein synthesis. Previous
work demonstrates that 2-ME exerts antigrowth and anti-
tumor effects in osteosarcoma cells but not in normal os-
teoblasts.4,5,30 Current findings reveal that 2-ME inhibits
cap-dependent protein synthesis in cancerous MG63 cells
without affecting protein synthesis in normal HOB. Thus,
our studies suggest that eIF4E/4E-BP system could play a
major regulatory role in 2-ME-mediated cell death, and
could be further explored as a potential target in the
treatment of osteosarcoma.
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